Wanbury informs about press release

09 Sep 2024 Evaluate

Wanbury has informed that it has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine. The global formulation market for Dextromethorphan is valued at USD 2,500 million for FY24, having grown by 7% over the past year. With the CEP certification, Wanbury is well positioned to initiate the commercial sales of this product in European markets.

The above information is a part of company’s filings submitted to BSE.

Wanbury Share Price

211.00 -11.00 (-4.95%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.